# OPK — OPKO Health · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** OPK  
**Sources:** 17  
**Published:** 2026-10-31  
**Canonical:** https://app.k3vl4r.com/research/deep-research-opk-opko-health-catalysts-narrative-risks-10394

---

## Recent Catalysts (roughly Aug–Oct 2026)

**Triggered conversion of 2029 convertible notes (Oct 1, 2026):** OPKO announced that its 3.75% Convertible Senior Notes due 2029 (~$121 million outstanding) became convertible through Dec 31, 2026 after the share price exceeded 130% of the $1.15 conversion price. OPKO elected to settle conversions entirely in shares (noteholders receive 869.5652 shares per $1,000 principal), and the window may extend beyond year-end 2026. [[2]](https://www.theglobeandmail.com/investing/markets/stocks/OPK-Q/pressreleases/4945821/opko-health-triggers-conversion-of-2029-convertible-notes/)

**Labcorp sale of BioReference assets:** OPKO agreed to sell select BioReference Health assets to Labcorp in a transaction worth up to $872 million (reported alternatively as $722 million upfront plus up to $150 million in earnout), intended to sharpen OPKO's biopharma focus and expand access to its 4Kscore test. [[13]](https://tickernerd.com/stock/opk-forecast/) [[14]](https://www.opko.com/investors/financial-information/financial-results) [[15]](https://www.opko.com/investors/financial-information)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-opk-opko-health-catalysts-narrative-risks-10394 (free to sign up)._